MHLW Adds Label Warnings To Astellas Protopic Ointment
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare added warning information to Astellas' atopic dermatitis drug Protopic (tacrolimus) ointment Sept. 25. The ministry ordered the company to add in the warning label that even though no link has been found, cases of lymphoma and skin cancer were reported. The ministry cited that there is on average one such case reported in Japan every year. (Click here for more - Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.